N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=48 DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
Dysfunctional Uterine Bleeding
Primary: Cessation of Bleeding Within 5 Days — 48 participants
Phase 3 N=105 Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Menorrhagia
Primary: Number of Participants With Successful Treatment of Heavy Menstrual Bleeding — 81; 83 Participants
Phase 4 N=18 Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy
Myomectomy; Surgical Blood Loss
Primary: Surgical Blood Loss — 761; 691 ml
Phase 3 N=19 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
Venous Thromboembolism · Menstruation
Primary: PBAC Scores — 292; 146 score on a scale
N/A N=79 Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users
Intrauterine Devices, Copper · Metrorrhagia · Menstruation
Primary: Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion…
Phase 3 N=165 Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
Menorrhagia
Primary: The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6) — -128.78; -17.7 milliliter (mL) — p=<0.001
Phase 4 N=284 Uterotonic Prophylaxis Trial
Hemorrhage
Primary: Number of Participants With Excessive Bleeding as Determined by the Composite Outcome Criteria — 78; 75 Participants — p=0.5
Phase 3 N=196 Efficacy and Safety Study of XP12B in Women With Menorrhagia
Menorrhagia · Heavy Menstrual Bleeding
Primary: Mean Reduction From Baseline in Menstrual Blood Loss (MBL) — 66; 18 mL
Phase 3 N=784 Safety Study of XP12B in Women With Menorrhagia
Menorrhagia · Heavy Menstrual Bleeding
Primary: Number of Subjects With at Least One Adverse Event During the Study — 678 participants
Phase 3 N=304 Efficacy and Safety of XP12B in Women With Menorrhagia
Menorrhagia · Heavy Menstrual Bleeding
Primary: Mean Reduction From Baseline in Menstrual Blood Loss (MBL) — 65; 44; 7 mL
Phase 4 N=67 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
Menorrhagia
Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
Phase 3 N=65 Intervention to End Recurrent Unscheduled Bleeding Trial
Contraception · Bleeding
Primary: Number of Bleeding/Spotting Days With Use of Ulipristal Acetate as Measured by Daily Bleeding Diaries — 7; 12 days — p=0.002
Phase 4 N=100 Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
Postpartum Hemorrhage · Uterine Atony
Primary: Uterine Tone Score — 4.7; 4.4 score on a scale
N/A N=44 Reduction of Endometritis After Cesarean Section With the Routine Use of Methergine
Endometritis
Primary: Endometritis Incidence — 0; 0 participants
Phase 4 N=58 Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users
Bleeding · Implants · Breakthrough Bleeding
Primary: Total Number of Days Without Bleeding or Spotting — 17.5; 16.7 days
Phase 3 N=231 Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.295; 0.012 Proportion of participants — p=< 0.0001
Phase 3 N=190 Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.292; 0.029 Proportion of participants — p=< 0.0001
N/A N=21 A Two-Phase Clinical Study of the Minerva AURORA Ablation System
Menorrhagia Due to Benign Causes
Primary: Reduction in Menstrual Blood Loss to Normal Levels at 12-months — 20 participants
N/A N=242 A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding
Menorrhagia
Primary: Primary Safety Endpoint: Number of Serious Adverse Events and Serious Device-related Adverse Events — 7; 0 Reports of events
Phase 2 N=150 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Phase 3 N=288 A Study of Tranexamic Acid (XP12B) in Women With Heavy Menstrual Bleeding
Menorrhagia
Primary: Participants With Treatment-Emergent Adverse Events (AEs) — 218; 1; 3; 60 participants
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=7 IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Von Willebrand Disease
Primary: >50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months — 71 percentage of participants
Phase 4 N=32 Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Change From Baseline Menses for Participant Perceived Blood Loss — 3; 1.9 score on a scale
Phase 4 N=106 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
Phase 4 N=37 Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)
Menorrhagia · Metrorrhagia · Medicated Intrauterine Devices
Primary: Number of Bleeding and Spotting Days — 16.8; 12.0 days
Phase 4 N=18 Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids
Heavy Menstrual Bleeding · Menorrhagia · Uterine Fibroids
Primary: Change in Self-Reported Menorrhagia Scores — 59.1; 25.4 score on a scale — p=0.11